Voice-Responsive Neurotherapies: A Future Avenue for Treating Neurological Disorders in 2025

Muhammad Talha[1], Laiba Shamim[2]

[1]King Edward Medical University, Lahore, Pakistan

[2]Jinnah Sindh Medical University, Karachi, Pakistan

Date of Submission: 3rd February 2025 Date of Acceptance:09th May 2025 Date of Publication: 15th May 2025

Dear Editor,

Neurological diseases like Parkinson's disease and epilepsy affect hundreds of millions worldwide and contribute significantly to the disability and health burden they entail. The incidence and impacts of these diseases increase as populations grow older, stressing healthcare systems in many of the directions identified by current pharmacological treatments, often deficient in precision, which can lead to significant side effects and a lack of efficacy [1]. The first experiments on whisper-modulated neurotherapies—a futuristic approach in which medicines release active compounds in response to specific frequencies of whispers, including whispered commands—aim to transform this technology into an appropriate methodology for targeted patient-controlled delivery into the brain. This technology, along with the anticipated patients and clinical trials, can play a remarkable role in neurology by enabling specific autonomy with targeted therapeutic intervention [2]. This letter attempts to understand the potential returns and hurdles concerning such therapy modalities, entitling it to demand agglutinated research and well-thought-out policy endeavors to resolve long-standing gaps in neurology.

Whisper-modulated neurotherapies develop from the advances made in both neuromodulation and bio-responsive drug delivery [2]. Currently available neuromodulation devices are deep brain stimulation and responsive neurostimulators. They provide therapy for movement disorders and seizure diseases that is flexible and targeted according to the specific needs of the patient or physiological change [1]. The next step would be the incorporation of sound-sensitive nanoparticles in medication release based on vocal commands. Evidence is still emerging on the more specific aspect of drug delivery triggered by whispers; however, generally adaptive, patient-responsive neuromodulation is swiftly advancing towards closed-loop systems in which therapy can take the input from wearable sensors [2]. These same enhancements would allow on-demand delivery of dopamine agonists to the above, which may reduce off-target effects, improving the lives of the over 10 million people living with Parkinson's[1]. Responsive systems have already proven effective in the area of epilepsy, where it has been shown that up to 70% of patients could be seizure-free under optimal treatment, but 30% remain refractory to standard therapies [3,4,5].

Despite their potential promise, whisper-modulated neurotherapies face multiple serious technical, regulatory, and ethical considerations [2,3]. First, the specificity of acoustic triggers is important to prevent unintentional release of the drug, while reliable, inexpensive devices should be tested for the detection and consequent response to a person's subtle vocal cues in diverse real-world environments [2]. Next in line are patient training and adherence; variations in vocalization could decrease efficacy, and not all patients may be able to consistently engage in the required frequency, especially those with advanced neurological impairments [2, 3]. In addition, there is unequal access to the advanced neuromodulation technologies themselves, with the vast majority of resources being concentrated in high-income countries, raising further questions about equity and global health justice [1,4]. Working through these challenges will therefore require interdisciplinary collaboration, clinical study substantiveness, and policy scaffolding to ensure safety, efficacy, and broad accessibility [2,4].

As the technologies of neuromodulation become increasingly capable, ethical considerations of autonomy, privacy, and misuse must be made. For instance, a risk of overdose and treatment being denied arises when vocal triggers are wrongly applied by patients or their caregivers.

Existing regulatory frameworks will have to adapt to prevent such occurrences and concurrently allow for innovation while ensuring patient safety [3,4]. With increasing reliance on therapy provided through wearable sensors and closed-loop systems, data privacy and security will take center stage [2]. Pilot studies and early clinical trials should give priority to populations who have not been well represented in earlier studies so that any benefit will be thereby distributed equitably and the synthetic technology will be adaptable to various cultural and linguistic settings [4].

Access this article online

Website: https://www.nepjol.info/index.php/NJN

DOI: 10.3126/njn.v22i1.78289

HOW TO CITE
Talha M, Shamim L. Voice-Responsive Neurotherapies: A Future Avenue for Treating Neurological Disorders in 2025. NJNS. 2025;22(1):57-58

Address for correspondence:
Laiba Shamim
Affiliation: Jinnah Sindh Medical University, Karachi, Pakistan
Email: Laibashamim015@gmail.com

ISSN: 1813-1948 (Print), 1813-1956 (Online)

In conclusion, whisper-modulated neurotherapies represent an audacious dream for the future of precision neurology, riding on the rapid development in neuromodulation and patient-responsive technologies [1,2]. The use of vocal cues in drug delivery could substantially increase treatment efficacy and patient autonomy in such conditions as Parkinson's or epilepsies [1,2,3,4]. To pave the way for such great ideas, these must be placed on top of the priority list of funding agencies, researchers, and regulators for interdisciplinary research, equitable access, and

References

1. Lozano AM, Lipsman N. Probing and regulating dysfunctional circuits using deep brain stimulation. Neuron. 2013;77(3):406–24.
2. Heck CN, King-Stephens D, Massey AD, et al. Neuromodulation in 2035: The Neurology Future Forecasting Series. Neurology. 2022;98(2):61–9.
3. Morrell MJ. Responsive cortical stimulation for the treatment of medically intractable partial epilepsy. Neurology. 2011;77(13):1295–304.
4. World Health Organization. Epilepsy: a public health imperative. Geneva: WHO; 2019.
5. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342(5):314–9.